ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "High-risk"

  • 2022 American Transplant Congress

    The High Acuity Index: A Posttransplant Prediction Score for High-MELD Patients

    C. R. Christmann1, A. Anand1, G. Handing1, A. Rana2

    1School of Medicine, Baylor College of Medicine, Houston, TX, 2Division of Abdominal Transplantation, Baylor College of Medicine, Houston, TX

    *Purpose: Patients with a very high Model for End-Stage Liver Disease (MELD) score are at significant short-term risk for death without liver transplantation. While many…
  • 2022 American Transplant Congress

    Evaluation of Hepatitis C Positive Donor to Hepatitis C Negative Recipient Kidney Transplant in a Highly Sensitized Patient Population

    A. T. Iaria, M. Martin, A. Hietpas, I. Tang, S. Koppe, I. Tzvetanov, E. Benedetti, C. Muran

    University of Illinois at Chicago, Chicago, IL

    *Purpose: This study assessed outcomes of hepatitis C virus (HCV) donor positive to recipient negative (D+/R-) kidney transplants (KT) in high immunologic risk patients. Literature…
  • 2022 American Transplant Congress

    Transplantation of Hepatitis C Viremic Donor Organs to Hepatitis C Nonviremic Recipients: A Retrospective Review

    M. Leick, M. Blaha, M. Henry

    Nebraska Medicine, Omaha, NE

    *Purpose: The advent of combination direct-acting antiviral (DAA) agents has improved the ability to treat hepatitis C virus (HCV) infections. As a result, utilization of…
  • 2021 American Transplant Congress

    Efficacy of Hope: Analysis of Quality HIV+ Deceased Donor Organ Availability

    G. E. Owens1, B. Shelton1, P. MacLennan1, D. Sawinski2, J. E. Locke1

    1Transplant, University of Alabama at Birmingham, Birmingham, AL, 2Transplant, University of Pennsylvania, Philadeplphia, PA

    *Purpose: The purpose of this study is to understand the number of organs actually available for HIV+ to HIV+ transplant utilizing data on a national…
  • 2021 American Transplant Congress

    Alemtuzumab vs Antithymocyte Globulin Induction in Hepatitis C Viremic Donors to Hepatis C Negative Kidney Transplant Recipients

    K. Walter, L. Mincemoyer, J. Giang, J. Suero, N. Shah, K. Szempruch

    University of North Carolina Medical Center, Chapel Hill, NC

    *Purpose: The optimal induction agent for kidney transplantation of hepatitis C virus nucleic acid test positive donors to negative recipients (HCV NAT D+/R-) is unknown.…
  • 2021 American Transplant Congress

    Psmp is Discriminative for Chronic Active Antibody-Mediated Rejection and Predicts Graft Risk After Kidney Transplantation

    Y. Fu, P. Zhan

    Tianjin First Central Hospital, Tianjin, China

    *Purpose: Chronic active antibody-mediated rejection (c-aABMR) is an intermediate process in the development of chronic antibody-mediated rejection (c-ABMR), a key problem in the long-term failure…
  • 2021 American Transplant Congress

    Implementation of a High-risk Medication Report for Waitlisted Liver Transplant Candidates

    M. M. Eiting1, H. Yeh2, M. Cote1, S. Shao1, A. B. Scherrer2, L. Dageforde2, N. Elias2, C. Rogers Marks1

    1Pharmacy, Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Boston, MA

    *Purpose: Use of high-risk medications (HRMs) at the time of liver transplant may lead to delays in surgery or peri-operative complications (bleeding, drug-drug interactions (DDI),…
  • 2021 American Transplant Congress

    T-cell-Mediated Immunity to Sars-cov-2 Defines Covid-19 Risk and Severity in Transplanted and Non-Transplanted Individuals and Associates with Myeloid-Derived Suppressor Cells

    C. Ashokkumar1, V. Rohan2, A. H. Kroemer3, S. Rao4, G. Mazariegos5, B. W. Higgs5, S. Nadig2, M. Ningappa5, T. Fishbein3, S. Subramaniam6, R. Sindhi7

    1Plexision, Pittsburgh, PA, 2Medical University of South Carolina, Charleston, SC, 3MedStar Georgetown Transplant Institute, Georgetown, DC, 4DHR Health Institute for Research and Development, Texas, TX, 5University of Pittsburgh, Pittsburgh, PA, 6University of California, San Diego, CA, 7University of Pittsburgh, pittsburgh, PA

    *Purpose: We assessed whether COVID-19-risk is enhanced by chronic immunosuppression, and is associated with suppressor cells.*Methods: We tested 66 COVID-19 patients, including 26 with solid…
  • 2021 American Transplant Congress

    Outcomes of Cytomegalovirus Status Determining Induction Therapy in Lung Transplant

    K. Heagler1, J. Lyons1, B. Bemiss2, P. Stracener1

    1Pharmacy, Loyola University Medical Center, Maywood, IL, 2Loyola University Medical Center, Maywood, IL

    *Purpose: At the study institution, basiliximab induction is withheld in lung transplant recipients who are cytomegalovirus (CMV) high risk due to concern for increased CMV…
  • 2021 American Transplant Congress

    Overall Survival by Best Overall Response with Tabelecleucel in Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant

    S. Prockop1, L. Gamelin2, R. Dinavahi2, Y. Sun2, N. Guzman-Becerra2, H. Parmar2

    1Memorial Sloan Kettering Cancer Center, New York, NY, 2Atara Biotherapeutics, South San Francisco, CA

    *Purpose: Tabelecleucel is an investigational, off-the-shelf, allogeneic Epstein-Barr virus (EBV)-specific T-cell immunotherapy being studied in patients (pts) with serious EBV-driven diseases, including post-transplant lymphoproliferative disease…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 15
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences